Advertisement

California medtech maker AqueSys caps a Series D funding round with $43.6 million and closes enrollment in an FDA clinical trial of its XEN Gel stent in treatment of glaucoma.

California ophthalmic devices maker AqueSys touted a couple of milestones today, landing a successful $43.6 million Series D funding round and closing enrollment in U.S. clinical trial of its XEN Gel stent for treatment of glaucoma.

The funding will allow AqueSys to make progress with its clinical trials, regulatory pursuits and commercialization efforts, president & CEO Ron Bache said in prepared remarks.

Advertisement
Advertisement